AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors (Revised)

AstraZeneca’s Enhertu secured its sixth EU indication via tumor-agnostic approval, extending label breadth and supporting commercial optionality. Separately, Datroway advanced toward a first-line TNBC (triple-negative breast cancer) EU nod after receiving a positive CHMP opinion. Net effect is incremental regulatory progress for both assets, with potential upside to future EU uptake.

Analysis

AstraZeneca’s Enhertu secured its sixth EU indication via tumor-agnostic approval, extending label breadth and supporting commercial optionality. Separately, Datroway advanced toward a first-line TNBC (triple-negative breast cancer) EU nod after receiving a positive CHMP opinion. Net effect is incremental regulatory progress for both assets, with potential upside to future EU uptake.